sexta-feira, 13 de novembro de 2026
PesquisarExplore
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· May 24, 2026

Goldman Sachs sees funds fleeing software for semiconductors as tech trade evolves

View original at seekingalpha.com
Goldman Sachs sees funds fleeing software for semiconductors as tech trade evolves [bull market buying - green stock data trading screen] bunhill Hedge funds and mutual funds are continuing a dramatic rotation out of software stocks and deeper into semiconductors, according to a new report from Goldman Sachs strategist…
Opening lines of the source · short snapshot — read the full document at the original

O que extraímos desta fonte

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • Both hedge funds and mutual funds remain overweight industrials and underweight information technology overall

    60% confidence
  • The S&P 500 currently trades at about 21 times forward earnings

    60% confidence
  • The rotation toward semiconductors reflects investors becoming more selective about which parts of the tech ecosystem can sustain earnings growth and justify elevated valuations

    60% confidence
  • Semiconductor exposure in hedge fund portfolios has climbed to a record high

    60% confidence
  • Mutual funds modestly raised cash levels from record lows, though allocations remain historically light

    60% confidence
  • Goldman's year-end 2026 target for the S&P 500 stands at 7,600, implying roughly 2% upside from current levels near 7,446

    60% confidence
  • Large-cap mutual funds gained 7% on average in 2026 but only 30% have outperformed their benchmarks, below the historical average of 37%

    60% confidence
  • Industrials and consumer staples are among the sectors trading at the richest premiums relative to their own historical ranges

    60% confidence
  • Hedge funds are overweight consumer discretionary shares while mutual funds remain underweight; the opposite pattern holds in financials where mutual funds are overweight and hedge funds are underweight

    60% confidence
  • Hedge fund net leverage has climbed back to the 85th percentile relative to the last five years, with gross leverage elevated versus historical norms

    60% confidence
  • Mutual funds are carrying their largest underweight position in software excluding Microsoft since 2012

    60% confidence
  • Hedge fund software allocations have dropped to their lowest level since 2019

    60% confidence
  • Goldman shared favorites Boeing, Mastercard, Marvell Technology, and Visa have returned 10% year to date, outperforming the equal-weight S&P 500 by roughly three percentage points

    60% confidence
  • Goldman Sachs forecasts S&P 500 earnings per share of $309 in 2026 and $342 in 2027

    60% confidence
  • The Nasdaq 100 trades closer to 26 times forward earnings

    60% confidence
  • The 10 largest S&P 500 companies now account for 40% of S&P 500 market capitalization and 36% of index earnings

    60% confidence
  • Hedge funds have returned 7% year to date, benefiting from the rebound in momentum stocks during the second quarter

    60% confidence

Data points we hold from this source

S&P 500 Index Fund · market share40 percent
O que sabemos · a inteligência por trás desta página
Ao vivo do substrato
O que estamos a ver
Late-2026 Biotech Catalyst Season: FDA Decisions and Pivotal Readouts Converge Across Oncology, Hepatology and Cardiometabolic
Mid-November 2026 is dense with scheduled biotech catalysts. The ivonescimab BLA PDUFA date is 2026-11-14, the lorundrostat PDUFA date is 2026-12-22, and Phase 3 ECLIPSE hepatitis delta data are due in Q1 2027. Alongside these, siRNA and antibody programs (plozasiran, elebsiran/tobevibart, ianalumab, nipocalimab) reported or presented data at AHA, AASLD, ACR and ASH, while Oryzon advanced iadademstat in AML with Spanish trial authorizations and a planned ALICE-3 Phase III. Late-stage data and regulatory milestones are driving the sentiment. A planned delisting (EGM 2026-11-19, application 2027-01-25) is a separate corporate-structure event with no clear link to the rest.
A nossa leitura dos dados ›
Sinais que acompanhamos
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Padrões que observamos ›
Onde as fontes divergem
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
Sinalizamos conflitos abertamente ›
Verificado recentemente
✓ Verificado com a fonte original
4,995
factos rastreados à sua fonte — e sinalizamos os que não se confirmam.
101 entidades acompanhadas4,995 factos verificados com a fonte5,577 documentos-fonte arquivados
Consulte estes dados → isubstrate.com